Trial Profile

A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Vinorelbine (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; Male breast cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms MOVIE

Most Recent Events

15 Jan 2025 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results (n=39) of tumor mutational burden-high and/or microsatellite instability-high cohort were presented at the 47th European Society for Medical Oncology Congress.
28 Jan 2022 Planned primary completion date changed from 14 Jan 2022 to 14 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com